HemeOx™: The First Clinically-Accurate Total Hemoglobin Pulse Oximeter – The Complete Oxygen Monitoring Picture!
Kestrel Labs, Inc., Boulder, Colorado, United States
Technologies for improved delivery of supplemental oxygen
Tech Brief: Kestrel Labs’ laser-based HemeOx™ pulse oximeter provides low-cost, continuous, and real-time monitoring of oxygen saturation, total hemoglobin, and hematocrit levels with unprecedented accuracy, even in cases of low oxygen saturation due to COVID-19 complications, thereby providing the first accurate real-time measure of oxygen content in the blood.
Mid-stage Startup (A or B)
FIGURES OF MERIT Value Proposition: Kestrel Labs has invented a patented, laser-based patient monitor that is a dramatic improvement over today’s LED-based pulse oximeters used throughout healthcare. The use of multiple lasers—located in the monitor to keep sensor costs low—allows accurate measurement of oxygen saturation, total hemoglobin, hematocrit, and oxygen content, thereby improving treatment decision making and reducing healthcare costs. The dramatic accuracy improvement in oxygen saturation measurement, coupled with its ability to monitor anemic status and blood oxygen content makes a compelling case for HemeOx™ being not only a crucial device for monitoring COVID19 patients but the new “standard of care” for pulse oximetry including in home healthcare. Kestrel Labs’ HemeOx™ Total Hemoglobin Pulse Oximeter has been systematically developed under an ISO 13485 compliant quality management system, with significant verification and validation testing both in the lab and on humans. Development is currently being supported by a commercialization grant from the National Institutes of Health, which in total has supplied over $7M in non-dilutive funding for the Company’s work, which includes HemeOx™ as well as work in noninvasive CO-oximetry and fetal oximetry. With significant development risk already retired, the next key steps for HemeOx™ are 510(k) clearance from FDA and market launch.